EXOSOMM

Company Overview

Snapshot

Founded in December 2021 by Prof. Shimon, Yaffa Elbaum-Shiff, and Regina Golan-Gerstl, EXOSOMM operates with 1–10 employees. The company has raised $4.52 million across 6 funding rounds from 6 investors. In May 2024, EXOSOMM completed its graduation from the HiCenter Ventures entrepreneurship program.

Business overview

EXOSOMM develops bioactive nutritional ingredients derived from natural milk exosomes, targeting the medical food and nutraceutical sectors. The company employs a patented, chemical-free technology to isolate these nanoparticles from whey, a dairy industry byproduct, preserving their active cargo of microRNAs that regulate immune responses and intercellular communication. EXOSOMM's primary solution addresses Inflammatory Bowel Diseases (IBD), such as Crohn's and Colitis, by offering a non-synthetic method to reduce inflammation and extend remission. This approach provides a sustainable, scalable, and clinically validated food-based alternative for managing chronic inflammatory and metabolic disorders, operating within the Health Tech & Life Sciences and Agriculture & Food Technologies sectors.

Strategic signal

In January 2025, EXOSOMM secured Seed funding from investors Tnuva Ventures. This investment validates EXOSOMM's innovative approach to developing bioactive nutritional ingredients from milk exosomes for medical foods and nutraceuticals, signaling strong investor confidence in its potential to address chronic inflammatory and metabolic disorders.

Company Intelligence Q&A

What was a significant recent achievement for EXOSOMM in the food tech industry?

In April 2025, EXOSOMM was recognized as one of the Top 10 finalists in the FoodTech World Cup, highlighting its innovative contributions to the food for health sector.

What progress has EXOSOMM made in clinical development for inflammatory bowel diseases?

In November 2023, EXOSOMM announced preparations for clinical trials of a natural supplement derived from cow milk to treat inflammatory bowel diseases like Crohn’s and colitis. The initial trial will involve 30 healthy individuals and is being conducted in collaboration with Hadassah Medical Center.

Which major food company is EXOSOMM partnering with for exosome extraction?

In November 2023, EXOSOMM partnered with Tnuva, Israel's largest food company, to extract exosomes from dairy milk processed in Tnuva plants, aiming to make the product available by early 2025.

What was EXOSOMM's pre-seed funding status?

In May 2023, EXOSOMM received $1 million in pre-seed investment from the Ofek-Galil incubator. This funding supports the company's development of a bioactive ingredient from upcycled whey for managing chronic metabolic disorders.

What was EXOSOMM's involvement in the Foodtech 2022 competition?

In October 2022, EXOSOMM reached the final stage of the Foodtech 2022 competition, showcasing its innovative developments in the food industry, specifically in the field of genetic improvement.